Table 2.
Blocking monoclonal antibodies of TIM-3
| Clone | Host | Model | Therapy | Effects | Ref. |
|---|---|---|---|---|---|
| RMT3-23 | C57BL/6 | Melanoma (B16-F10) | Antibody therapy | Tumor growth↓ | 48 |
| C57BL/6 | Melanoma (B16-F10) | Antibody therapy | Treg suppressive functions↓ | 49 | |
| C57BL/6 | Melanoma (B16-F10) | Tumor vaccination (FVAX) | Inhibition of tumor growth NK cell infiltration ↑ NK cell activation ↑ |
50 | |
| C57BL/6 | Melanoma (B16-F10) | DNA vaccine (gp100) | Inhibition of tumor growth NK cell infiltration ↑ NK cell activation ↑ |
50 | |
| C57BL/6 | Melanoma (B16-F10) | DNA vaccine (TRP2) | Tumor growth↓ Interferons↑ IL-12↑ NK cell activation ↑ |
44 | |
| C57BL/6 | Colon cancer (MC38) | Chemotherapy (Cisplatin) | Tumor growth↓ | 44 | |
| C57BL/6 | Colon cancer (MC38) | Antibody therapy | Tumor growth↓ CD4+ and CD8+ T cell ↑ IFN-γ production ↑ |
48 | |
| BALB/c | Colon cancer (CT26) | Antibody therapy | Tumor growth↓ CD4+ and CD8+ T cell ↑ | 48 | |
| BALB/c | Colon cancer (CT26) | Antibody therapy | Treg suppressive functions ↓ | 49 | |
| C57BL/6 | Colon cancer (CT26) | Antibody therapy | Treg suppressive functions ↓ | 49 | |
| C57BL/6 | Sarcoma (WT3) | Antibody therapy | Tumor growth↓ IFN-γ production ↑ | 48 | |
| C57BL/6 | Prostate carcinoma (TRAMP-C1) | Antibody therapy | Tumor growth↓ | 48 | |
| C57BL/6 | Ovarian cancer (ID8) | Combination with anti-CD137 | Tumor growth↓ CD4+ and CD8+ T cell ↑ CD4+FoxP3+ Treg ↓ CD11b+Gr-1+MDSC cell ↓ |
51 | |
| C57BL/6 | Phagocytosis of apoptotic cells | Antibody therapy | Phagocytosis / cross presentation by CD8+ DC↓ Auto-antibody production↑ | 52 | |
| 8B.2C12 | BALB/c | Colon cancer (CT26) | Antibody therapy | tumor growth ↓ IFN-γ production ↑ | 49 |
| 2E2 | PBMC | Melanoma | Peptide vaccination | Proliferation of NY-ESO-1+ CD8+ T cell ↑ IFN-γ production ↑ |
45 |
| PBMC | Melanoma | Peptide vaccination | Proliferation of NY-ESO-1+ CD8+ T cell ↑ IFN-γ, TNFα↑ |
46 | |
| PBMC | Melanoma | In vitro blockade | NK cell-mediated cytotoxicity ↑ IFN-γ production ↑ NK cell proliferation ↑ |
53 | |
| AF2365 | PBMC | Melanoma | In vitro blockade | NK cell-mediated cytotoxicity ↑ | 53 |
| ATIK2a | BALB/c | Acute myeloid leukemia (AML) | Antibody-dependent cell-mediated cytotoxicity | Elimination of TIM-3 expressing leukemia stem cell (LSC) | 54, 55 |
| 344823 | Human NK cell | Cytotoxic assay | In vitro blockade | NK cell-mediated cytotoxicity ↓ | 56 |
| 344801 | Human NK cell | Cytotoxic assay | In vitro blockade | NK cell-mediated cytotoxicity ↓ | 56 |